Drug Profile
Research programme: stem cell therapies - Sephos Biotherapeutics
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Sephos Biotherapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Canada (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in Canada (Parenteral)
- 03 Jun 2014 Preclinical trials in Acute myeloid leukaemia in Canada (Parenteral)